In vivo gene editing advances with Intellia’s trial start, grant

Intellia took CRISPR-based in vivo gene editing two steps forward this week with the start of the first clinical trial of a systemically delivered therapy and the announcement that the biotech was awarded a grant to develop in vivo CRISPR therapies for sickle cell disease. 

On Monday, Intellia Therapeutics Inc. (NASDAQ:NTLA) announced the first patient was treated with NTLA-2001 in a Phase I trial for transthyretin amyloidosis (ATTR). ...